Wikisage, the free encyclopedia of the second generation, is digital heritage

Epilepsy: Difference between revisions

From Wikisage
Jump to navigation Jump to search
(World Health Organization)
Line 7: Line 7:
It is difficult to distinguish between genetic and cryptogenic syndromes.
It is difficult to distinguish between genetic and cryptogenic syndromes.


Morbility data is difficult to interpret when WHO<ref>http://www.who.int/en/</ref> states 50-70 millions persons<ref>(Li et al 2014)</ref> suffers '''epilepsy'''<ref>(Chung 2015)</ref>
Morbility data is difficult to interpret when [[World Health Organization|WHO]]<ref>http://www.who.int/en/</ref> states 50-70 millions persons<ref>(Li et al 2014)</ref> suffers '''epilepsy'''<ref>(Chung 2015)</ref>


nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance wih [[antiepileptic drug|AED]]<ref>(Davis et al 2008)</ref>
nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance wih [[antiepileptic drug|AED]]<ref>(Davis et al 2008)</ref>

Revision as of 23:52, 25 July 2015

Classification of ethiology could divided in four categories:

  • idiopathic epilepsy
  • symptomatic epilepsy
  • provoked epilepsy
  • cryptogenic epilepsy

[1] It is difficult to distinguish between genetic and cryptogenic syndromes.

Morbility data is difficult to interpret when WHO[2] states 50-70 millions persons[3] suffers epilepsy[4]

nonadherence appears to be associated with increased health care costs, nevertheless XR-medicine appears as strategy to overcome compliance wih AED[5]

Medicines

type  ,,, ,,,,
INN  Generic slow release
carbamazepine  normal xr
lamotrigine  normal xr
levetiracetam  normal xr
oxcarbazepine  ... xr
phenitoin  ... xr
valproate  xr
topiramate  xr

AED

ILAE Classification

[6] [7] [8] [9] ILAE Overview

See also

A new perspective for Epileptic Disorders

Links

Prevalence and cost of nonadherence with antiepileptic drugs in an adult managed care population

The Efficacy of Leviteracetam versus Carbamazepine for Epilepsy: A Meta-Analysis

Dravet's syndrome

References

References:
  1. The etiologic classification of epilepsy
  2. http://www.who.int/en/
  3. (Li et al 2014)
  4. (Chung 2015)
  5. (Davis et al 2008)
  6. http://www.who.int/mediacentre/factsheets/fs999/en/
  7. epilepsy is not resolved. Epilepsy Currents 14 2014
  8. https://www.ligaepilepsia.cl/epilepsias/tipos-de-epilepsia
  9. Annie T Berg et al.2010 Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009 Epilepsia 51 676-685